BÜHLMANN Quantum Blue® Citations Archives

Therapeutic Drug Monitoring in Crohn’s Disease Patients

Bodini, G. et al. Therapeutic Drug Monitoring in Crohn's Disease Patients, A Comparison Between Homogenous Mobility Shift Assay and Point of Care Method. UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain. P1750. Read Citation BÜHLMANN Quantum Blue® IFX is for Research Use Only in the US. Not for use in diagnostic procedures in the US.

Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R., Barreiro-de Acosta, M., Lorenzo-Gonzalez, A. & Dominguez-Muñoz, J. E. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study. J. Clin. Gastroenterol. (2016) PMID: remission, whereas concentrations >300 μg/g allow predicting relapse with a high probability at any

The New Biosimilar of IFX SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

BÜHLMANN Quantum Blue® IFX Citation: Magro, F., Rocha, C. et al. P229 The new biosimilar of IFX SB2 can be quantified by IFX-optimized therapeutic drug monitoring assays. Journal of Crohns and Colitis. 2018, Jan. DOI: 10.1093/ecco-jcc/jjx180.356. BÜHLMANN Quantum Blue® IFX is for Research Use Only in the US. Not for use in diagnostic procedures in the US. Health

A Pilot Study Using Point of Care Testing for IFX and Faecal Calprotectin in IBD Patients

BÜHLMANN Quantum Blue® IFX Citation: Sophie Restellini, Talat Bessissow, Carolyne Lemieux, Che-Yung Chao, Gary Wild, Ernest Seidman, Alain Bitton, Peter L. Lakatos, Waqqas Afif. P711 A pilot study using point of care testing for IFX and faecal calprotectin in IBD patients with a secondary loss of response. Journal of Crohn's and Colitis. 2018 Jan. DOI: 10.1093/ecco-jcc/jjx180.838. Highlight from

Correlation of Rapid Point-of-Care vs Send-Out Fecal Calprotectin Monitoring in Pediatric Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL extended Citation: Rodriguez, A. et al. Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. World J Gastrointest Pharmacol Ther 8(2):127-130. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.127. Highlight from this Publication “In summary, we present the first correlation study of rapid POC calprotectin testing in a pediatric IBD

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory BowelDisease Can J Gastroenterol Hepatol. 2016;2016:2483261. Epub 2016 Sep 28.DOI:10.1155/2016/2483261. PMID: 27774443. This Canadian study represents how FCAL testing is utilized in the field for monitoring disease activity in IBD. The reference for the cut-off

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663. Highlight from this Publication "The FC test effected a change in management 51.3% of the time and receipt of the result was associated with a reduction

Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance IFX Therapy

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R. Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Peña C, Benitez Estevez AJ, Dominguez-Muñoz JE., Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance IFX Therapy. J Clin Gastroenterol. 2016 Feb;50(2):147-51. doi: 10.1097/MCG.0000000000000312. Highlight from this Publication “We found FC to

Comparison of the Liaison® Calprotectin Kit with a Well-Established Point of Care Test (Quantum Blue — Bühlmann-Alere®) in Terms of Analytical Performances and Ability to Detect Relapses Amongst a Crohn Population in Follow-up

Quantum Blue® fCAL Citation: Delefortrie, Q. Schatt P, Grimmelprez A, Gohy P, Deltour D, Collard G, Vankerkhoven P. Comparison of the Liaison® Calprotectin kit with a well-established point of care test (Quantum Blue — Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up, Clinical Biochemistry. 2016 Feb;49(3):268-73. doi: 10.1016/j.clinbiochem.2015.10.010

Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study,

Quantum Blue® fCAL Citation: Voiosu T Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B. Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study, J Gastrointestin Liver Dis. 2014 Sep;23(3):273-8. doi: 10.15403/jgld.2014.1121.233.thv. Highlight from

Category: BÜHLMANN Quantum Blue® Citations

Therapeutic Drug Monitoring in Crohn’s Disease Patients

Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease

The New Biosimilar of IFX SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

A Pilot Study Using Point of Care Testing for IFX and Faecal Calprotectin in IBD Patients

Correlation of Rapid Point-of-Care vs Send-Out Fecal Calprotectin Monitoring in Pediatric Inflammatory Bowel Disease

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance IFX Therapy

Comparison of the Liaison® Calprotectin Kit with a Well-Established Point of Care Test (Quantum Blue — Bühlmann-Alere®) in Terms of Analytical Performances and Ability to Detect Relapses Amongst a Crohn Population in Follow-up

Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study,

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US